Stopping the bleeding early

Hemophilia was supposed to be the no-brainer for gene therapy, but so far just about every company that has gone after the indication has failed. The latest is Avigen Inc., which last week discontinued development of its Coagulin B for hemophilia B after seeing results of a Phase I trial. Instead, the